Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and safety of PT009 (budesonide + formoterol) vs PT005 (formoterol) in moderate to very severe COPD
2016-000155-28Phase 3Completed
- Sponsor
- Pearl Therapeutics
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of budesonide + formoterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Pearl Therapeutics. Primary endpoint: Morning pre-dose trough FEV1. Started Sep 2016; status: completed.
02
Drugs
budesonide + formoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2016-000155-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000155-28.